{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"NZHIGLHQWQLPPC-UHFFFAOYSA-N","prefName":"CUMYL-TSINACA","symbol":"CUMYL-TSINACA","iupacName":"1-(4-methylphenyl)sulfonyl-N-(2-phenylpropan-2-yl)indazole-3-carboxamide","aliases":["CUMYL-TsINACA"],"cas":null,"pubchemCid":"168322650","chebiId":null,"smiles":"CC1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C(=N2)C(=O)NC(C)(C)C4=CC=CC=C4","molecularFormula":"C24H23N3O3S","molecularWeight":433.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/168322650"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: a chemically synthesised molecule that exists in no living organism. It belongs to the class of indazole-3-carboxamides, bearing a tosyl group on the N1 nitrogen and a cumyl group on the amide.","originNote":"A fully synthetic molecule, absent from the cannabis plant. According to Pulver et al. (2022), it belongs to the newer synthetic cannabimimetics, a family that forms the largest category of new psychoactive substances in the European Union. It was identified in illicit products seized in Germany.","discovered":""},"pharmacology":{"summaryFr":"CUMYL-TSINACA, whose systematic name is 1-(4-methylphenylsulfonyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide, is a synthetic cannabinoid distinguished by a tosyl group on the nitrogen at position 1 of the indazole ring. Described in 2022 by Pulver et al. from products seized in Germany, it behaves as a full agonist at CB1 (Emax of 228 %), but with a very low affinity (Ki of 292 nM) and low functional activity (EC50 of 31 µM). The authors judge its low thermal stability and low potency unfavourable for psychoactive use, which does not prove that it is harmless. No human, pharmacokinetic or toxicological data are published in the sources consulted.","receptorSummaryFr":"A full agonist at CB1, with low affinity and low potency. At hCB1, the authors report a Ki of 292 nM, a maximal efficacy (Emax) of 228 %, and an EC50 of 31 µM, indicating low functional activity (Pulver et al., 2022). The abstract reports no measurement at CB2 or at other targets, and no such data were found in the sources consulted.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":54,"reported":"Ki 292 nM (hCB1, Pulver et coll., 2022) ; EC50 31 µM ; Emax 228 %","confidence":"medium"}],"references":[{"label":"Pulver et coll., élucidation de la structure du Cumyl-TsINACA trouvé dans des produits illicites en Allemagne, Drug Testing and Analysis, 2022","pmid":"35338591","doi":"10.1002/dta.3261","url":"https://pubmed.ncbi.nlm.nih.gov/35338591/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (listes des conventions de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-TSINACA, CID 168322650","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/168322650"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":10},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":5},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":8},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":12},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":10}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure was found for this molecule in the sources consulted: its status falls under national legislation. At international level, it does not appear on the INCB Green List (2026 edition, 1971 Convention schedules).","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Cumyl-TsINACA is not named in the ANSM consolidated list of narcotics (updated 16 February 2026); its structure does not meet the clause covering indazole-3-carboxamide derivatives, which requires on the nitrogen at position 1 a substituent of the type alkyl, haloalkyl, halobenzyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, methyl-oxane, 1-(N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whereas the molecule carries a tosyl group (arylsulfonyl). It is therefore not classified as a narcotic in the texts consulted.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Pulver et coll., élucidation de la structure du Cumyl-TsINACA trouvé dans des produits illicites en Allemagne, Drug Testing and Analysis, 2022","pmid":"35338591","doi":"10.1002/dta.3261","url":"https://pubmed.ncbi.nlm.nih.gov/35338591/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (listes des conventions de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CUMYL-TSINACA, CID 168322650","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/168322650"}],"meta":{"slug":"cumyl-tsinaca","url":"https://en.phytogrammes.com/wiki/cumyl-tsinaca","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}